Telomir Pharmaceuticals (NASDAQ:TELO) Releases Earnings Results, Beats Expectations By $0.04 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) announced its quarterly earnings data on Wednesday. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.04, FiscalAI reports.

Telomir Pharmaceuticals Stock Performance

TELO stock remained flat at $1.27 during mid-day trading on Friday. The company’s stock had a trading volume of 43,538 shares, compared to its average volume of 140,711. Telomir Pharmaceuticals has a 52 week low of $1.05 and a 52 week high of $3.10. The firm has a 50-day moving average of $1.32 and a 200 day moving average of $1.33. The firm has a market capitalization of $43.66 million, a P/E ratio of -3.88 and a beta of -0.21.

Analyst Upgrades and Downgrades

TELO has been the topic of several recent research reports. Wall Street Zen raised shares of Telomir Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Zacks Research raised Telomir Pharmaceuticals to a “hold” rating in a report on Wednesday, March 18th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in shares of Telomir Pharmaceuticals in the fourth quarter valued at about $53,000. Geode Capital Management LLC lifted its stake in Telomir Pharmaceuticals by 14.0% in the 4th quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock valued at $297,000 after buying an additional 27,519 shares in the last quarter. Raymond James Financial Inc. raised its holdings in shares of Telomir Pharmaceuticals by 4,101.9% during the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock valued at $105,000 after acquiring an additional 73,547 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Telomir Pharmaceuticals in the second quarter worth approximately $62,000. Finally, Qube Research & Technologies Ltd purchased a new position in Telomir Pharmaceuticals in the 2nd quarter valued at $33,000.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.